USANA Health Sciences, Inc. (NYSE: USNA) has reported its financial results for the fiscal fourth quarter and fiscal year ended January 3, 2026. The company's net sales for the fourth quarter of 2025 were $226.2 million, reflecting a 6% increase from the same period in 2024. However, the net loss for the quarter was $1.8 million, down from a net income of $4.5 million in the fourth quarter of 2024. Diluted earnings per share (EPS) were reported at minus $0.10, a decrease from $0.23 in the same period the previous year. The adjusted diluted EPS for the quarter was $0.60, down 6% from the fourth quarter of 2024. Adjusted EBITDA for the fourth quarter of 2025 was $27.3 million, a 7% increase from the same period in 2024.
For the full fiscal year 2025, USANA reported net sales of $925.3 million, marking an 8% year-over-year growth. However, the net earnings for the fiscal year were $10.8 million, a significant decrease from $42.0 million in 2024. The diluted EPS for the full year was $0.58, down 74% from the previous year. The adjusted diluted EPS for fiscal year 2025 was $1.93, representing a 25% decrease from 2024. Adjusted EBITDA for the full year 2025 was $101.3 million, an 8% decrease from the previous year.
USANA's active customers declined from 454,000 in the fourth quarter of 2024 to 387,000 in the fourth quarter of 2025. Similarly, the active monthly subscribers for its brand Hiya were reported at 181,700.
Looking ahead, the company provided its outlook for fiscal year 2026. USANA expects consolidated net sales to be between $925 million and $1.0 billion, with net earnings projected to range from $20.3 million to $26.6 million. The company also anticipates diluted EPS to be between $1.11 and $1.45, and adjusted diluted EPS to be between $1.95 and $2.29. The adjusted EBITDA for fiscal year 2026 is expected to range from $101.3 million to $109.3 million.
USANA's CEO, Kevin Guest, mentioned that the company began to see signs of stabilization in active customer counts, particularly in its core nutritional business, with modest sequential growth in net sales in key markets including mainland China, the United States, and Canada.
Despite the challenges faced, USANA continued to execute its diversification strategy towards an omnichannel model. The company's Hiya brand posted solid year-over-year growth, and its Rise Wellness brand saw strong momentum with sales tripling, albeit from a small base in 2024.
USANA's fiscal 2025 net sales were primarily driven by a full-year contribution from Hiya, while net sales in the core nutritional business declined 8%, reflecting a challenging environment for customer acquisition in key markets.
The company's balance sheet showed it ended the year with $158 million in cash and cash equivalents and $14 million of debt. Additionally, USANA repurchased 927,000 shares in fiscal 2025 for an investment of $28 million, with approximately $34 million remaining under the current share repurchase authorization as of January 3, 2026.
USANA's CFO, Doug Hekking, noted that the reported GAAP results for the fourth quarter and full year reflected the impact of two notable items, including a non-cash impairment charge and cost realignment initiatives. Looking ahead to fiscal 2026, the company is projecting consolidated net sales in a range of flat to 8% growth.
USANA is optimistic about its prospects, with plans to leverage its foundation in the nutrition business and expand beyond its legacy channel to connect with a greater number of health-conscious consumers worldwide. The company aims to strengthen its brand relevance through an omnichannel approach, deepen consumer engagement, empower brand partners, and execute with discipline to accelerate profitable growth and deliver sustainable long-term value for shareholders. As a result of these announcements, the company's shares have moved 1.53% on the market, and are now trading at a price of $21.93. For more information, read the company's full 8-K submission here.
